Loading...
Market
What will be the top-selling antidepressant drug in the US by the end of 2024?
2
Resolution / Starting Odds
High-dose psilocybin • 25%
Escitalopram • 25%
Sertraline • 25%
Other • 25%
Pharmaceutical sales data and market analysis reports
Story
High-Dose Psilocybin Backed by Prince Harry Shows Antidepressant Potential
Aug 22, 2024, 08:32 AM
A new study has highlighted the potential of high-dose psilocybin, the active ingredient in magic mushrooms, as an effective treatment for depressive symptoms. According to a meta-analysis, high-dose psilocybin may be as effective as the SSRI drug escitalopram in reducing depressive symptoms, although the effect size was small. The study has gained attention partly due to the endorsement by Prince Harry, who supports the use of mega-doses of psilocybin as a mood-boosting therapy. Experts have reviewed the findings and agree that psilocybin could be as effective as current antidepressants when administered in high doses.
View original story
Similar markets
Mounjaro • 25%
Zepbound • 25%
Trulicity • 25%
Other • 25%
Takeda Pharmaceutical • 25%
Teva Pharmaceutical • 25%
Eli Lilly • 25%
Other • 25%
Mounjaro • 25%
Zepbound • 25%
Trulicity • 25%
Humalog • 25%
Migraine medication • 25%
COVID-19 medication • 25%
Flu medication • 25%
Respiratory illness medication • 25%
Covid vaccine • 25%
Paxlovid • 25%
Other Pharmaceutical Product • 25%
Other Vaccine • 25%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Less than 1 million units • 25%
1 to 2 million units • 25%
2 to 3 million units • 25%
More than 3 million units • 25%
Zepbound • 25%
Wegovy • 25%
Saxenda • 25%
Other • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Cancer drugs • 25%
COVID-19 treatment • 25%
Vaccines • 25%
Other pharmaceuticals • 25%
Skyrizi • 25%
Rinvoq • 25%
Humira • 25%
Other • 25%